



#6741  
NW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : Jackowski et al.

INVENTION: : MACROGLOBULIN BIOPOLYMER MARKERS  
INDICATIVE OF INSULIN RESISTANCE

SERIAL NUMBER : 09/993,295

FILING DATE : November 23, 2001

EXAMINER: : (not assigned yet)

GROUP ART UNIT : 1741

ATTORNEY DOCKET NO. : 2132.099

RECEIVED  
MAR 20 2002  
TC 1700

TRANSMITTAL LETTER

CERTIFICATE UNDER 37 CFR 1.8(a)  
I hereby certify that this correspondence is being  
deposited with the U.S. Postal Service as First Class mail  
in an envelope addressed to Commissioner for  
Patents, Washington, D.C. 20231 on 3-5-02

Susan Hess

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Please find enclosed for filing:

X Information Disclosure Statement  
X PTO-1449  
X References

RECEIVED  
MAY 21 2002  
TC 1700

Respectfully submitted,

Date: 3/5/2002

By: Ferris H. Lander

Ferris H. Lander  
Registration No. 43,377  
McHale & Slavin, P.A.  
4440 PGA Boulevard, Suite 402  
Palm Beach Gardens, FL 33410  
Telephone: (561) 625-6575



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : Jackowski et al.

INVENTION: : MACROGLOBULIN BIOPOLYMER MARKERS  
INDICATIVE OF INSULIN RESISTANCE

SERIAL NUMBER : 09/993,295

FILING DATE : November 23, 2001

EXAMINER: : (not assigned yet)

GROUP ART UNIT : 1741

ATTORNEY DOCKET NO. : 2132.099

RECEIVED

MAR 20 2002

TC 1700

RECEIVED

MAY 21 2002

INFORMATION DISCLOSURE STATEMENT

TC 1700

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being  
deposited with the U.S. Postal Service as First Class mail  
in an envelope addressed to Commissioner for  
Patents, Washington, D.C. 20231 on 3-5-02

Susan Hess

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56, the references cited on the accompanying form PTO-1449 are hereby brought to the attention of the Examiner for independent evaluation. A copy of each reference or its U.S. equivalent is enclosed. The references were cited in the specification and their relevancy is set forth therein.

Applicants submit that the present invention is patentable over these references.

Date: 3/5/2002

Respectfully Submitted,

Ferris H. Lander

Ferris H. Lander  
Reg. No. 43,377  
McHale & Slavin, P.A.  
4440 PGA Boulevard, Suite 402  
Palm Beach Gardens, FL 33410  
Telephone: (561) 625-6575

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
2132.099APPLICATION NO.  
09/993,295

O (REV. 2-88)

MAR 14 2002

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

APPLICANT  
JACKOWSKI et al.FILING DATE  
11/23/01GROUP  
1741

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,062,935	11/91	Schlag et al.			
	6,020,208	02/00	Hutchens et al.			
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
Y	WO 93/24834	12/93	PCT		X	
Y	WO 90/14148	11/90	PCT		X	
Y	WO 98/07036	02/98	PCT			X
Y	WO 98/07036	02/98	PCT (translation)		X	

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Y	Takahashi et al., "Rapid and Sensitive Immunoassay for the Measurement of Serum S100B Using Isoform-specific Monoclonal Antibody", Clinical Chemistry 45, No. 8, (1999) pp. 1307-1311.
Y	Richter et al., "Composition of the peptide fraction in human blood plasma: database of circulating human peptides", Journal of Chromatography B; 726 (1999) pp. 25-35.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.